Aprea Therapeutics (APRE) Corporate presentation summary

Strategic focus and pipeline

• Specializes in precision medicine oncology, developing targeted therapies for biomarker-defined cancers.

• Positioned at the forefront of synthetic lethality, focusing on DNA damage response (DDR) pathways.

• Pipeline includes WEE1 inhibitor (APR-1051), ATR inhibitor (ATRN-119), and DYRK1 inhibitor (APR-1602), with multiple clinical and preclinical programs.

• Transitioning from broad chemotherapy to safer, precision-guided therapies addressing unmet needs.

• Robust intellectual property portfolio with global patent coverage for key assets.

Clinical development and data

• APR-1051, a structurally differentiated WEE1 inhibitor, shows preliminary monotherapy activity in Phase 1 trials, including partial responses and stable disease in biomarker-defined tumors.

• Early clinical data indicate favorable safety profile with limited high-grade adverse events and manageable toxicity.

• Confirmed partial response in uterine carcinosarcoma and durable stable disease in rectal and HPV+ head and neck cancers.

• Biomarker-driven expansion path supported by responses across multiple tumor types and genetic alterations.

• Interim clinical data for APR-1051 expected in Q4 2026, with dose escalation completion targeted for Q2 2027.

Differentiation and preclinical insights

• APR-1051 designed for high potency and minimal off-target inhibition, especially reduced PLK1 inhibition, potentially expanding the therapeutic window.

• Preclinical studies show synergy with chemotherapy, immuno-oncology, and DDR agents across cancer models.

• Minimal PLK1 co-inhibition may reduce toxicity and enhance efficacy compared to other WEE1 inhibitors.